Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Initiates Phase I Trial of Second-Gen TTR Amyloidosis Drug


Alnylam Pharmaceuticals this week said that it has begun dosing patients in a phase I study of its siRNA-based transthyretin-mediated amyloidosis treatment ALN-TTR02.

The trial is a randomized, single-blind, placebo-controlled, single-ascending dose study that will enroll about 32 healthy volunteers, the company said.

The primary endpoint is safety and tolerability of a single dose of ALN-TTR02, and study subjects will be enrolled in five sequential cohorts of increasing doses ranging from 0.01mg/kg to 0.50 mg/kg. Secondary objectives include serial measurement of circulating TTR serum levels through at least day 56 following a single dose.

ALN-TTR02 is a second-generation version of ALN-TTR01, which was found to safely trigger statistically significant reductions in serum levels of TTR protein, which characterizes TTR amyloidosis (GSN 12/1/2011).

The new drug uses a different delivery technology, the so-called MC3 lipid, which Alnylam has said is proprietary to the company. Tekmira Pharmaceuticals, which developed the lipid nanoparticles used in ALN-TTR01, has sued Alnylam over the rights to the MC3 technology.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.